Thursday, November 8, 2012
Publication and contact
Xenograft mouse model for
pediatric acute megakaryoblastic leukemia (AMKL)
A mouse xenograft model for
pediatric AMKL could help identify new treatments for the cancer. Blast cells
from the blood or bone marrow of patients with pediatric AMKL were injected
into immunocompromised mice, with six of eight samples leading to successful
engraftment. The models recapitulated aspects of the human disease, including
low blast counts in the blood. In the model, the aurora
kinase A (AURKA;
decreased leukemic blast levels and the incidence of paralysis and increased
survival compared with placebo. Next steps include using this model to assess
the efficacy of additional therapeutic candidates.
Takeda Pharmaceutical Co. Ltd.'s
is in Phase III testing to treat peripheral T cell lymphoma (PTCL). The
compound also is in Phase II testing or earlier to treat other cancers.
Published online Nov. 8, 2012
Patent and licensing status
Thiollier, C. et al. J.
published online Oct. 8, 2012;
Contact: Thomas Mercher, Institut National de la Santé et de
la Recherche Médicale (INSERM), Vellejuif, France
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]